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Abstract
Background Mutations in podocyte and basement membrane
genes are associated with a growing spectrum of glomerular
disease affecting adults and children. Investigation of familial
cases has helped to build understanding of both normal phys-
iology and disease.
Methods We investigated a consanguineous family with a
wide clinical phenotype of glomerular disease using clinical,
histological, and new genetic studies.
Results We report striking variability in severity of nephrop-
athy within an X-linked Alport syndrome (XLAS) family.
Four siblings each carried a mutant COL4A5 allele,
p.(Gly953Val) and p.(Gly1033Arg). Two boys had signs lim-
ited to hematuria and mild/moderate proteinuria. In striking
contrast, a sister presented with end-stage renal disease
(ESRD) at 8 years of age and an infant brother presented with
nephrotic syndrome, progressing to ESRD by 3 years of age.
Both were subsequently found to have homozygous variants
in MYO1E, p.(Lys118Glu) and p.(Thr876Arg). MYO1E is a
gene implicated in focal segmental glomerulosclerosis and it
encodes a podocyte-expressed non-muscle myosin. Bioinfor-
matic modeling demonstrated that the collagen IV-alpha3,4,5
extracellular network connected via known protein–protein
interactions to intracellular myosin 1E.
Conclusions COL4A5 and MYO1E mutations may summate
to perturb common signaling pathways, resulting in more se-
vere disease than anticipated independently. We suggest
screening for MYO1E and other non-COL4 ‘podocyte gene’
mutations in XLAS when clinical nephropathy is more severe
than expected for an individual’s age and sex.
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Introduction
In 1927, Cecil Alport described an inherited nephropathy [1]
with the teenage male proband having Ban attack of influenza
followed by a large increase of blood and albumin in the urine^.
Alport noted that the nephropathy could progress to uremia and
it was inherited through females. Subsequently, the disease was
called X-linked Alport syndrome (XLAS). Affected individuals
have glomerular basement membrane (GBM) ultrastructural de-
fects. Transmission electronmicroscopy (TEM) generally shows
Bdiffuse thickening and splitting with strikingly irregular outer
and inner contours^, although, especially in women and chil-
dren, Birregular alternation of thick and abnormally thin GBM^
or Bdiffusely thin GBM^ can occur [2].
Mutations of COL4A5 encoding the alpha-5 chain of col-
lagen IV, a GBM component, cause XLAS [3]. A minority of
AS individuals have mutations of autosomal genes encoding
collagen IV alpha-3 or alpha-4 chains [4], which form
heterotrimers with alpha-5. The same collagen IV network is
found in ear and eye BMs and AS can feature sensorineural
deafness and ophthalmic complications, although these are
uncommon in children [5, 6]. The generally less aggressive
course of XLAS nephropathy in women is explained by the
fact that they carry both a normal and mutant COL4A5 allele
versus males who have only the mutated allele [5]. In men,
more severe nephropathy can correlate with predicted null
versus missense mutations [2, 7]. However, as now described,
there exists another genetic explanation underlying variation
in the severity of XLAS nephropathy.
Methods
Genetic studies
Samples were collected following informed consent. COL4
Sanger sequencing was performed as previously described
[8]. Analysis of X-inactivation was also performed as previ-
ously reported [9].
Whole exome sequencing
Library preparation, sequencing, and data generation was per-
formed in the Genomics Core Facility of the Biomedical Re-
search Centre at Guy’s and St Thomas’ Hospitals and King’s
College London. DNA libraries were prepared from 3 μg
dsDNA using SureSelect Human All Exon 50Mb kit (Agilent
Technologies). Samples were multiplexed (four samples on
each lane) and 100 base pair paired end sequencing was per-
formed on Illumina HiSeq system. The mean coverage was
136× (97 % of target sequenced with depth of ≥5×, 95 %
≥10×, and 92 % ≥20×). Sequence data were aligned to the
GRCh37/hg19 human reference genome using Novoalign,
variants were called with SAMtools and annotated via multi-
ple passes through Annovar. Exome sequencing data analysis
was performed at the University of Bristol (Academic Renal
Unit). Variants of interest were confirmed using Sanger se-
quencing (Eurofins MWG Operon, Germany). Primers used
for MYO1E were published by Mele et al. [10] and for
COL4A5 by Martin et al. 1998 [11]; the KAPA HiFi PCR
Kit (Kapa Biosystems) was used for the amplification.
Transmission electron microscopy
Samples were fixed for at least 1 h in Neutral Buffered Formalin
10 % V/Vand fixative was replaced with 2.5 % glutaraldehyde
in 0.1M sodium cacodylate buffer (pH 7.4) for at least 3 h. Post-
fixation samples were incubated in 1 % proprietary (TAAB)
osmium tetroxide solution and rinsed in 0.1 M sodium
cacodylate buffer followed by dehydration in alcohols graded
up to 100 % ethanol. Samples were incubated in propylene
oxide (TAAB) to remove the alcohol and heated to 40 °C in
50/50 mix propylene oxide/resin (TAAB Araldite CYC212)
followed by 100 % resin for 2 h before embedding in resin
blocks for 12 h at 60 °C. Ultrathin 120-nm sections were cut
with a Leica UC7 ultramicrotome and placed on copper grids.
Grids were stained in 2 % uranyl acetate 10 min before the
addition of Reynolds’ lead citrate for 10 min. The grids were
observed in a JEOL 100CX transmission electron microscope.
Protein interaction network
Protein interaction network analysis was performed using
Cytoscape (version 2.8.1) [12]. Collagen IV alpha-3,4,5 and
myosin 1E were mapped onto a merged human interactome
built from the Protein Interaction Network Analysis platform
Homo sapiens network (release date, June 28, 2011) and Mus
musculus network (release date, June 28, 2011) [13], the ex-
tracellular matrix (ECM) interactions database MatrixDB (re-
lease date, August 26, 2010) [14], and a literature-curated
database of integrin-based adhesion-associated proteins [15].
Topological parameters were computed using the
NetworkAnalyzer plug-in [16].
Results
Wide phenotypic variation in a family with inherited
glomerular disease
Five siblings from a consanguineous family of Pakistani ori-
gin (Fig. 1) were investigated in the Royal Manchester Chil-
dren’s Hospital’s Renal Genetic Clinic. The proband (IV.3)
presented at the age of 2 years with pyrexia and hematuria.
Following resolution of the febrile illness, he had persistent
microscopic hematuria and mild proteinuria (protein/
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creatinine ratio 24–50 mg/mmol; normal <20). Plasma creat-
inine, complement levels, and blood pressure were normal. A
renal biopsy at 3 years was normal by light microscopy, with
no immune deposits. On TEM, the GBM showed Bvariable
thickness and some lamination^ (Fig. 2a, b). Given these
changes, after parental consent, COL4A5 Sanger sequencing
was undertaken [8]. IV.3 carried two hemizygous variants,
confirmed using bidirectional sequencing. The first, c.2858G
> T; p.(Gly953Val) in exon 33, was already associated with
XLAS [17], with the mutated amino acid highly conserved in
evolution as assessed with bioinformatics software Alamut
v2.0. The second was c.3097G > C; p.(Gly1033 Arg) in exon
35. This was previously unreported but is predicted to inter-
rupt the GLY-X-Y repeat structure of the collagenous domain
in the alpha-5 chain. Other missense changes in this region
have been reported in AS [18]. Ophthalmology and audiom-
etry examinations were normal in IV.3 and in his other siblings
with renal disease, as presented below.
The proband’s older sister (IV.1) had been unwell for sev-
eral years before emigrating from Pakistan. Aged 8 years, her
estimated glomerular filtration rate (eGFR) was 10 ml/min/
1.73 m2 and a renal biopsy was not performed due to the
associated risks. She commenced dialysis and at 9 years old
underwent deceased donor renal transplantation; she has sat-
isfactory graft function 8 years later. IV.1 was found to be
heterozygous for the mutant COL4A5 allele. To explain her
severe renal presentation, we hypothesized that she had
skewed X-inactivation of her normal COL4A5 allele. We
found an X-inactivation ratio of 90:10 in her leukocyte
DNA, reported in only 4 % of adult females [19].
IV.3’s older brother (IV.2) presented aged 5 years with fe-
ver and microscopic hematuria. His eGFR of 54 ml/min/
1.73 m2 later improved to 104 ml/min/1.73 m2. Over the next
year, he had persistent proteinuria (269–423 mg/mmol) and,
although normotensive, he was treated with the angiotensin
converting enzyme inhibitor (ACEI), enalapril. This follows
evidence and guidelines [20–23] that renin-angiotensin sys-
tem blockade may slow renal disease progression in XLAS
males. At age 9 years, his proteinuria (162 mg/mmol) and
renal function were stable. He was found to be hemizygous
for the same mutant COL4A5 allele. A renal biopsy was not
performed. The youngest female sibling (IV.4) is well and has
normal urinalysis and COL4A5 alleles.
The youngest male sibling (IV.5) presented at 6 months old
with macroscopic hematuria and nephrotic syndrome (urinary
protein/creatinine 6220 mg/mmol). He was treated with intra-
venous furosemide and 20 % human albumin replacement
therapy. A renal biopsy was normal by light microscopy but
TEM revealed GBM thickening and lamination with foot pro-
cess fusion (Fig. 2c, d). A trial of glucocorticoids was
discontinued at 28 days, having no effect on proteinuria; he
was subsequently maintained on oral ACEI and diuretics,
which prevented edema despite hypoalbuminemia (10–11 g/
l). Over 3 years, his renal function deteriorated and peritoneal
dialysis was commenced.
The mother, III.5, was investigated at age 39. She had micro-
scopic hematuria but was normotensive. Her eGFR was 82 ml/
min/1.73 m2 and her 24-h urinary protein was 1.70 g. She began
treatment with ACEI. She carries the mutant COL4A5 allele.
Two of her brothers (III.6 and III.7) died with end-stage renal
disease (ESRD) in their twenties, and her mother (II.5) had
ESRD aged 58 years. The children’s father has normal urinalysis
and borderline hypertension and carries a normal COL4A5 al-
lele. His deceased father (II.3) had a history of nephropathy.
I:1 I:2 I:3 I:4 I:5 I:6
II:1 II:2 II:3 II:4 II:5
III:1 III:2 III:3 III:4 III:5 III:6 III:7 III:8 III:9 III:10






Top geneotype COL4A5 (blue)
Bottom genotype MYO1E (red)
Fig. 1 Family pedigree. Black
filled symbols represent
individuals affected by end-stage
renal disease (ESRD) and black
filled symbols with a line through
are those individuals who had
ESRD as a cause of death.
Hatched symbols represent
individuals with hematuria and or
proteinuria. Genotypes for
COL4A5 are indicated above the
symbols (blue) and for MYO1E
the genotype is indicated below
(red). Each filled semicircle
represents a mutant allele. †
indicates age of death
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Whole exome sequencing identifies mutations inMYO1E
Nearly a century after Alport’s description of XLAS, we ap-
preciate that mutations in a growing list of genes encoding
podocyte proteins can cause glomerular disease [24–29].
Notably, coinheritance of a variant allele of one such
gene, podocin-encoding NPHS2, predisposes to protein-
uria and ESRD in individuals with hematuria and
COL4A4 mutations [30]. In this family, the parents are
first cousins so we hypothesized that a second, autoso-
mal recessive, condition modified the severity of ne-
phropathy. Accordingly, we performed next generation
sequencing in IV.5, which included analysis of all genes
currently associated with podocytopathy (ACTN4,
ADCK4, ALG1, ANLN APOL1, ARHGAP24, ARHGDIA,
CD151, CD2AP, COL4A3, COL4A4, COL4A5, COQ2,
COQ6, CTL4A, CUBN, DGKE, E2F3, EMP2, INF2,
ITGA3, ITGB4, LAMB2, LMNA, LMX1B , MYH9,
MYO1E, NPHS1, NPHS2, NXF5, PAX2, PDSS2, PLCe1,
PMM2 , PTPRO , SCARB2 , SMARCAL1 , SYNPO ,
TRPC6, TTC21B, WT1 and ZMPSTE24), as described
in [29]. This confirmed the COL4A5 mutations, and that
COL4A3 and COL4A4 were normal. However, we dis-
covered that IV.5 also carried two homozygous missense
variants in MYO1E affecting highly conserved amino
acids c.352A > G; p.(Lys118Glu) and c.2627C > G;
p.(Thr876Arg). Furthermore, IV.1, the sister with ESRD,
was also homozygous for these variants (Fig. 1). IV.2
was wild type and IV.3, IV.4 and the parents were
heterozygous.
Collagen IV alpha-5 and myosin 1E share protein
interactions
We undertook a protein–protein interaction network analysis
[31] based on known protein–protein interactions. As depicted
in Fig. 3, myosin 1E and collagen IV-alpha-3,4,5 have shared
interactors in a network comprising a number of key matrix











Fig. 2 Native renal biopsies
(a–d). Transmission electron
micrograph images from IV.3
(a, b) and IV.5 (c, d), with higher
magnification images in the
bottom row (b, d). In IV.3, the
GBMwas thin, with a diameter as
low as 92 nm. There were also
focal areas of lamination (black
arrow in a). In IV.5, glomerular
basement membranes extra
cellular matrix (GBMs) were
irregular, with thick and thin
portions, with lamination (black
arrow in c). There was extensive
podocyte foot process fusion and
a generalized increase in the
mesangium
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and cytoskeletal elements. Thus, COL4A5 andMYO1Emuta-
tions may summate to perturb common cell-matrix signaling
pathways.
Discussion
In this kindred, the coinheritance of COL4A5 mutations and
homozygous MYO1E variants were associated with more se-
vere kidney disease within a family initially recognized to
have XLAS. Skewed X inactivation may be a second contrib-
uting factor in IV.1 and possibly protected against the more
rapid progression to renal failure seen in IV.5.
MYO1E encodes a podocyte-expressed non-muscle myo-
sin [10, 32], with TH1 and TH2 domains, functioning in
invadosomes; actin-rich adhesion structures modulating
ECM degradation and invasion [33]. In vitro, myosin 1E over-
expression protects podocytes from puromycin nephrotoxicity
[32], while in vivo targeted Myo1e deletion in podocytes
causes proteinuria, foot process effacement, and GBM thick-
ening [34]. MYO1E biallelic, generally missense, mutations
have been reported in children with focal segmental
glomerulosclerosis and glucocorticoid-resistant proteinuria
[10, 35, 36]. The variant p.(Lys118Glu) in the myosin head
motor domain is a novel variant and is predicted to be delete-
rious. The p.(Thr876Arg) variant in the myosin tail domain is
also predicted to be deleterious and it is recorded in dbSNP
(rs147596471) with an allele frequency of 0.003 but only in
the heterozygous state. To our knowledge, IV.5 is the youngest
individual reported to date who has biallelic MYO1E muta-
tions and who has had a renal biopsy; instead of sclerosis, only
severe GBM and foot process anomalies were seen.
This extraordinary family demonstrates that mutations of
two podocyte genes can explain a highly variable renal phe-
notype, inexplicable by conventional pedigree analysis. The
mutations summate to generate life-threatening nephropa-
thies, and insights are highly relevant to genetic counseling.
We suggest screening for MYO1E and other non-COL4
‘podocyte gene’ mutations in XLAS when clinical nephropa-
thy is more severe than expected for an individual’s age and
sex. Furthermore, the increasing use of global and unbiased
genetic analysis with next-generation sequencing is likely to
reveal disease-modifying variants across the range of human
genetic disease.
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Fig. 3 Protein–protein interaction network for collagen IV and myosin
1E. This interaction network was created from a database of known
protein–protein interactions. The direct (1-hop) interactors for collagen
IV-α3,4,5 and myosin 1E were identified and arranged within the net-
work. The circles (nodes) represent proteins within the interaction net-
work. The lines (edges) represent known interactions. The size of the node
represents the degree of connections and the color of the node represents
the number of interactions. The network comprises 43 nodes and 151
edges. Network analysis was performed using Cytoscape (version
2.8.1) [12]. Collagen IV alpha-3,4,5 and myosin 1E were mapped onto
a merged human interactome built from the Protein Interaction Network
Analysis platform Homo sapiens network (release date, 28 June 2011)
and Mus musculus network (release date, 28 June 2011) [13], the ECM
interactions databaseMatrixDB (release date, 26 August 2010) [14] and a
literature-curated database of integrin-based adhesion-associated proteins
[15]. Topological parameters were computed using the NetworkAnalyzer
plug-in [16]
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